Navigation Links
ETH Zurich study on salmonella self-destruction
Date:8/21/2008

ETH Zurich biologists, led by Professors Martin Ackermann and Wolf-Dietrich Hardt, in collaboration with Michael Doebeli of the University of British Colombia in Vancouver (CN), have been able to describe how random molecular processes during cell division allow some cells to engage in a self-destructive act to generate a greater common good, thereby improving the situation of the surviving siblings.

Survival strategy

The biologists investigated this unusual biological concept using the pathogenic salmo-nella bacteria as an example. Diseases caused by salmonellae are very unpleasant and even life-threatening. When contaminated food is consumed for example, egg-based foods or chicken and meat salmonella bacteria enter the gastro-intestinal tract where it triggers infection. Vomiting and diarrhoea can last for days.

Normally, salmonellae grow poorly in the intestine because they are not competitive with other bacteria of the gut. However, this dynamic changes if salmonellae induce an in-flammatory response, namely diarrhoea, which suppresses the other bacteria. The in-flammation is triggered by salmonellae penetrating into the intestinal tissues. Once in-side, salmonellae is killed by the immune system. This in turn creates a conflict: salmo-nellae are either suppressed by the other bacteria in the gut, or die while trying to elimi-nate these competitors.

As Ackermann, Hardt and Doebeli report, salmonellae have found a surprising solution to this conflict. Inside the gut, the samonella bacteria forms two groups that engage in job-sharing. A first group invades the tissue, triggers an inflammation, then dies. A sec-ond group waits inside the gut until the inactivation of the normal intestinal flora gives them an opportunity to strike.This second group then multiplies unhindered.

Random processes and self-sacrifice

What determines whether an individual salmonella bacterium cell self-sacrifices,
'/>"/>

Contact: Professor Dr. Wolf-Dietrich Hardt
wolf-dietrich.hardt@micro.biol.ethz.ch
41-446-325-143
ETH Zurich/Swiss Federal Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
2. ETH Zurich professor Ari Helenius awarded Benoist Prize
3. New ETH Zurich article published in scientific journal Nature
4. ETH Zurich competence center ESC introduces energy strategy
5. ETH Zurich researchers develop antibody test
6. IBM and ETH Zurich form strategic partnership in nanoscience
7. ETH Zurich and IBM improve diagnosis of osteoporosis
8. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
9. A study by the MUHC and McGill University opens a new door to understanding cancer
10. Study begins to reveal clues to the cause and progression of sepsis
11. Clones on task serve greater good, evolutionary study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the October 2011 issue of Experimental Biology and ... Medical Center led by Stephen Tsang, MD, Ph.D have ... model for retinitis pigmentosa (RP) using novel bipartite gene ... by progressive degeneration of rod photoreceptors (which mediate night ...
... The carbon dioxide we exhale and the odors our skins ... hunt for human hosts to bite and spread diseases such ... at the University of California, Riverside have now performed experiments ... that transmit yellow fever and dengue -- respond to plumes ...
... Irvine, Calif., Sept. 30, 2011 A glucosamine-like dietary ... sclerosis, according to a UC Irvine study. UCI,s ... oral N-acetylglucosamine (GlcNAc), which is similar to but more ... and function of abnormal T-cells that in MS incorrectly ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Flight patterns reveal how mosquitoes find hosts to transmit deadly diseases 2Glucosamine-like supplement suppresses multiple sclerosis attacks 2
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
... (NYSE Amex: PIP ) announced today further ... SparVax™.  The new vaccine is being developed to provide ... emergency.  The Company completed its first cGMP manufacturing run ... ongoing and expected to be completed in December. ...
... Blood Pressure , aka Hypertension , is ... mostly ineffective.   Fortunately , Hypertensive patients ... methods that are both effective, inexpensive, and risk free. ... help reduce   Chronic Heart/Cardiovascular Disease patients,   ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8PharmAthene Progresses Second Generation rPA Anthrax Vaccine 2PharmAthene Progresses Second Generation rPA Anthrax Vaccine 3PharmAthene Progresses Second Generation rPA Anthrax Vaccine 4Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: